Arthur Przybyl - ANI Pharmaceuticals Insider

ANI Pharmaceuticals Inc -- USA Stock  

USD 69.24  0.7  1%

CEO and President and Director

Mr. Arthur S. Przybyl is President, Chief Executive Officer, Director of the Company
Age: 59  CEO Since 2013      
218-634-3500  www.biosantepharma.com
Przybyl is an experienced healthcare executive in a career that spans over 25 years and includes the management of both specialty pharmaceutical and medical device companies. From August 2002 through January 2009, Mr. Przybyl served as President and Chief Executive Officer of Akorn, Inc., a NASDAQlisted specialty pharmaceutical company that manufactures and markets ophthalmic, liquid and lyophilized injectable, and vaccine drug products. Prior to Akorn, Mr. Przybyl was President of privatelyheld company Hearing Innovations, Inc. and President and Chief Operating Officer of NASDAQlisted company Bioject, Inc., both of which are medical device companies. During his career, Mr. Przybyl has held several sales and marketing management positions, including Senior Vice President, Sales and Marketing for International Medication Systems, Inc. and Director, Corporationrationrationrate Marketing and National Accounts for LyphoMed, Inc., both specialty pharmaceutical companies.

Arthur Przybyl Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.09 % which means that it generated profit of $7.09 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 4.25 % meaning that it created $4.25 on every $100 dollars invested by stockholders.
The company currently holds 151.28 M in liabilities with Debt to Equity (D/E) ratio of 82.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals Inc has Current Ratio of 3.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 8 records

CEO Since

Jeff BaxterVBI Vaccines Inc
2009
MRCP MBBSDimension Therapeutics Inc
N/A
Jeffrey BachaDel Mar Pharmaceuticals Inc
2018
Dror HaratsVascular Biogenics Ltd
2001
Barry SimonNantKwest Inc
2015
Curtis LockshinVBI Vaccines Inc
2015
Ryan WattsDenali Therapeutics Inc
2016
Annalisa JenkinsDimension Therapeutics Inc
2014

Entity Summary

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals Inc (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 108 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Price Ceiling Movement Now
   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
Hide  View All  NextLaunch Price Ceiling Movement
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ANI Pharmaceuticals Inc to your portfolio

Top Management

ANI Pharmaceuticals Inc Leadership Team
Robert Brown, Chairman, MBA
Charlotte Arnold, President, MBA
Mark Ginski, President, Ph.D
Robert Schrepfer, VP, MBA
Daniel Raynor, Director
Stephen Carey, President
David Sullivan, VP, Ph.D
Karen Quinn, President
James Marken, VP
Peter Lankau, Director
Fred Holubow, Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO
Thomas Penn, Director

Stock Performance

ANI Pharmaceuticals Performance Indicators